Navigation Links
Michael J. Fox Foundation Commits Up to $2 Million to Improve Drug Delivery for Parkinson's Disease
Date:3/25/2008

NEW YORK, March 25 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced the launch of a new funding program, Improving Delivery of Parkinson's Disease Therapeutics to the Brain. This $2-million initiative aims to stimulate research addressing two major challenges to the development of transformative treatments for Parkinson's disease. The first challenge is the need for non-invasive drug delivery technologies allowing therapeutics to cross the blood-brain barrier. The second challenge is the need to more precisely understand how molecules move inside the central nervous system in order to target treatments to specific regions of the brain.

The blood-brain barrier, a thin membrane of tightly packed cells, creates a wall between most parts of the brain and the rest of the circulatory system. While this barrier is critical for protecting the brain by keeping out bacteria and other harmful agents, it also prevents entry by therapeutic molecules that could potentially impact the symptoms and progression of PD and other neurological disorders. Research is required to find new delivery technologies that would safely and reliably allow drugs to pass into the brain.

Even when a molecule of interest is able to pass the blood-brain barrier, researchers face an enormous obstacle in targeting the treatment to the proper area of the brain. The Foundation therefore aims to spark research to improve understanding of the movement and diffusion of molecules inside the brain.

"Advances in molecular biology and our understanding of Parkinson's disease continue to open new therapeutic avenues for investigation," said Katie Hood, CEO of The Michael J. Fox Foundation. "But every therapeutic, no matter how promising, currently faces one major challenge: how do we get it into the targeted region of the brain, at appropriate levels, in a controlled and reproducible fashion? Improving on this status quo would be a major leap forward in the discovery of life-changing treatments for Parkinson's disease."

The difficulties posed by the blood-brain barrier affect not only "small-molecule" therapeutics -- the chemical compounds that make up the majority of drugs brought to market by big pharma -- but also create an obstacle to the delivery of "large-molecule" treatments involving the use of proteins, including trophic factors such as GDNF, and other biologics being developed by biotechs. Genetic material, used in gene silencing or gene therapy approaches, also cannot cross the blood-brain barrier and currently can be delivered only via surgical intervention.

Molecular size may also affect movement inside the brain, where molecules face an obstacle course of both physical impediments and chemical limitations that impact their ability to get where they need to go. Factors that may be at work include brain vasculature (arrangement of blood vessels), the structure of the brain's white matter (the tissue through which messages pass between different areas within the nervous system) and even brain changes brought on by Parkinson's disease itself.

This program is open to academic and industry investigators alike for research projects of up to two years' duration. Pre-proposals will be reviewed by the Foundation's scientific staff and a panel of scientific experts and must be submitted online by May 15, 2008. Information about submitting pre-proposals online can be found on the Foundation's Web site (http://www.michaeljfox.org). Applicants whose pre-proposals meet the review criteria will be invited to submit full proposals. Funding is anticipated by October 2008.

A conference call with MJFF Research Programs staff to further clarify the aims and goals of this initiative will be held April 7, 2008, at 12 p.m. U.S. Eastern Time. Researchers wishing to participate in the call must RSVP to conferencecalls@michaeljfox.org and will receive an e-mail reply with call-in details.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $115 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... Use Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the ... every edge they can get while staying in compliance with FDA rules. , ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that ... detail to the athletic wear market with the launch of their FlipBelt Crops. , ... their essentials securely at their fingertips while at the gym, on the trail, or ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines ... Artificial Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... information that offers a more comprehensive understanding of the organization’s business and machine ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: